← Back to Screener
Lifevantage Corporation Common Stock (Delaware) (LFVN)
Price$5.13
Favorite Metrics
Price vs S&P 500 (26W)-55.40%
Price vs S&P 500 (4W)-7.14%
Market Capitalization$61.08M
P/E Ratio (Annual)6.23x
Indicated Dividend Yield (Annual)3.77%
All Metrics
P/CF (Annual)5.14x
Book Value / Share (Quarterly)$2.58
P/TBV (Annual)4.73x
Indicated Dividend (Annual)$0.18
Revenue Growth (3Y)3.45%
Cash Flow / Share (Quarterly)$0.13
Payout Ratio (TTM)28.13%
Price vs S&P 500 (YTD)-26.54%
Gross Margin (TTM)78.75%
Net Profit Margin (TTM)3.74%
EPS (TTM)$0.60
10-Day Avg Trading Volume0.12M
EPS Excl Extra (TTM)$0.60
Revenue Growth (5Y)-0.38%
EPS (Annual)$0.76
Dividend / Share (Annual)$0.17
ROI (Annual)28.30%
Gross Margin (Annual)80.37%
Net Profit Margin (5Y Avg)2.86%
Cash / Share (Quarterly)$0.80
P/E Basic Excl Extra (TTM)7.77x
Revenue Growth QoQ (YoY)-27.79%
EPS Growth (5Y)-0.84%
P/E Normalized (Annual)6.23x
ROA (Last FY)13.63%
Revenue Growth TTM (YoY)-0.99%
EBITD / Share (TTM)$0.90
ROE (5Y Avg)18.34%
Operating Margin (TTM)4.26%
Cash Flow / Share (Annual)$0.85
P/B Ratio1.85x
P/B Ratio (Quarterly)2.37x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)0.24x
Net Interest Coverage (TTM)21.00x
ROA (TTM)11.56%
EPS Growth QoQ (YoY)-88.79%
EV / EBITDA (TTM)4.34x
EPS Incl Extra (Annual)$0.76
Current Ratio (Annual)1.87x
Quick Ratio (Quarterly)0.80x
3-Month Avg Trading Volume0.18M
52-Week Price Return-66.30%
EV / Free Cash Flow (Annual)4.84x
P/E Incl Extra (TTM)7.77x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$2.32
P/S Ratio (Annual)0.27x
Asset Turnover (Annual)3.18x
52-Week High$15.00
Operating Margin (5Y Avg)4.02%
EPS Excl Extra (Annual)$0.76
CapEx CAGR (5Y)-12.55%
Tangible BV CAGR (5Y)1.20%
26-Week Price Return-46.65%
Quick Ratio (Annual)0.89x
13-Week Price Return-21.64%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.03x
Enterprise Value$50.898
Revenue / Share Growth (5Y)1.98%
Asset Turnover (TTM)3.09x
Book Value / Share Growth (5Y)3.70%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)2.51x
Pretax Margin (Annual)5.36%
Cash / Share (Annual)$1.63
3-Month Return Std Dev62.61%
Gross Margin (5Y Avg)80.70%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)-3.22%
EBITDA Interim CAGR (5Y)-28.54%
ROE (Last FY)28.30%
Net Interest Coverage (Annual)14.92x
EPS Basic Excl Extra (Annual)$0.76
P/FCF (TTM)13.76x
Receivables Turnover (TTM)96.73x
EV / Free Cash Flow (TTM)30.03x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$0.60
Receivables Turnover (Annual)73.21x
ROI (TTM)23.32%
P/S Ratio (TTM)0.29x
Pretax Margin (5Y Avg)3.90%
Revenue / Share (Annual)$17.60
Tangible BV / Share (Annual)$2.77
Forward P/E7.62x
Free OCF CAGR (5Y)-7.66%
Price vs S&P 500 (52W)-101.40%
P/E Ratio (TTM)7.77x
EPS Growth TTM (YoY)6.21%
Year-to-Date Return-22.40%
5-Day Price Return14.63%
EPS Normalized (Annual)$0.76
ROA (5Y Avg)8.61%
Net Profit Margin (Annual)4.29%
Month-to-Date Return10.65%
Cash Flow / Share (TTM)$0.49
EBITD / Share (Annual)$1.18
EPS Growth (3Y)47.22%
Operating Margin (Annual)5.34%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)16.30x
ROI (5Y Avg)18.34%
P/E Excl Extra (TTM)7.77x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$0.60
P/TBV (Quarterly)2.64x
Payout Ratio (Annual)21.08%
P/B Ratio (Annual)4.69x
Dividend / Share (TTM)$0.17
Inventory Turnover (TTM)2.45x
Pretax Margin (TTM)4.42%
Book Value / Share (Annual)$2.79
Price vs S&P 500 (13W)-24.50%
Net Margin Growth (5Y)-2.78%
Dividend Yield (TTM)3.62%
Beta0.53x
P/FCF (Annual)5.81x
Revenue / Share (TTM)$16.48
ROE (TTM)23.32%
52-Week Low$3.90
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
LFVNLifevantage Corporation Common Stock (Delaware) | 0.29x | -0.99% | 78.75% | -0.84% | $5.13 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
LifeVantage develops and distributes nutraceutical supplements and skincare products, including Protandim, LifeVantage TrueScience, Axio energy drinks, and PhysIQ. The company operates in ten countries across North America, Asia-Pacific, and Europe. Its products are positioned as scientifically-validated wellness solutions for health-conscious consumers.